Quick Answer
CRISPR Therapeutics AG reported R&D Expense of $284.81 million for fiscal year 2025.
CRISPR Therapeutics AG R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $284.81M | -8.2% |
| 2024 | $310.24M | -19.9% |
| 2023 | $387.33M | -16.1% |
| 2022 | $461.64M | +35.6% |
| 2021 | $340.57M | +53.8% |
| 2020 | $221.38M | +23.4% |
| 2019 | $179.36M | +57.6% |
| 2018 | $113.77M | +63.0% |
| 2017 | $69.80M | +65.3% |
| 2016 | $42.24M | +235.9% |
| 2015 | $12.57M | +731.0% |
| 2014 | $1.51M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $58.90M | -28.3% | -15.7% |
| June 30, 2025 | $69.89M | -12.8% | -3.6% |
| March 31, 2025 | $72.48M | -4.8% | -11.8% |
| September 30, 2024 | $82.16M | -9.4% | +2.5% |
| June 30, 2024 | $80.17M | -21.1% | +5.2% |
| March 31, 2024 | $76.17M | -23.8% | -16.0% |
| September 30, 2023 | $90.70M | -22.2% | -10.7% |
| June 30, 2023 | $101.56M | -17.6% | +1.6% |
- CRISPR Therapeutics AG showed a decrease of -8.2% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, CRISPR Therapeutics AG’s r&d expense has grown by 18723.9% (from $1.51 million to $284.81 million).
- The most recent figure is from CRISPR Therapeutics AG’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: